Metastatic breast cancer: focus on endocrine sensitivity
Mené sur 524 patientes atteintes d'un cancer du sein HR+ de stade avancé ou métastatique, cet essai international de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du fulvestrant et de l'astronazole, en hormonothérapie de première ligne
Hormone receptor expression in breast cancer indicates disease subtypes that can be effectively managed with endocrine therapies.1,2 The use of selective oestrogen modulators or degraders showed efficacy in the management of metastatic and primary disease.1 Aromatase inhibitors are a class of endocrine drugs that inhibit aromatase activity with an effect on oestradiol concentrations contributing to their efficacy primarily in postmenopausal breast cancer.2 Clinical resistance to these drugs associated with progression of disease either during adjuvant therapy or in patients with advanced disease is a significant therapeutic challenge.
The Lancet , commentaire, 2015